CMN Global Clinical Trials Database 2.0 - Terms of Use & License Agreement
CRISPR Medicine News (CMN) Global Clinical Trials Database 2.0
Effective Date: 2026-02-17
These Terms of Use (“Terms”) govern access to and use of the CRISPR Medicine News (CMN) Global Clinical Trials Database 2.0 (the “Database”), operated by CRISPR Medicine News (“CMN,” “we,” “us,” or “our”).
By accessing or using this website or the Database, you agree to be bound by these Terms. If you do not agree, you may not access or use the Database.
License Grant
Subject to compliance with these Terms, CMN grants users a limited, non-exclusive, non-transferable, revocable license to access and use publicly available portions of the Database for personal, educational, clinical, or non-commercial research purposes.
No ownership rights are transferred under this license.
Ownership & Intellectual Property
The Database, including its structure, taxonomy, classifications, curation methodology, annotations, design, organization, and presentation, constitutes proprietary intellectual property owned by CRISPR Medicine News.
While underlying clinical trial information may originate from publicly disclosed sources (including registries, publications, patents, press releases, and company disclosures), the compilation, organization, contextualization, and analytical enhancements represent original editorial and analytical work protected under applicable copyright, database protection, and intellectual property laws.
All third-party trademarks referenced remain the property of their respective owners.
Permitted Use
Users may:
Search and view Database content
Use information for academic citation, internal research, clinical awareness, or non-commercial analysis
Cite “CRISPR Medicine News Global Clinical Trials Database 2.0” as the source in publications or presentations
Prohibited Conduct
Users may not, without prior written consent from CRISPR Medicine News:
Systematically extract, scrape, crawl, mine, harvest, index, or otherwise collect Database content
Download, copy, reproduce, redistribute, republish, or publicly display substantial portions of the Database
Create derivative databases, datasets, or competing products based on the Database structure, taxonomy, classifications, annotations, or curated framework
Use Database content for commercial resale, licensing, competitive intelligence services, automated aggregation, or product development
Use Database content to train, fine-tune, validate, benchmark, or populate artificial intelligence (AI) systems, machine learning models, large language models, or other automated decision-making technologies
Circumvent or attempt to circumvent technical safeguards, access controls, subscription limitations, rate limits, or security mechanisms
Automated Access & Data Extraction Restrictions
Automated access to the Database, including the use of bots, scripts, crawlers, spiders, scraping tools, AI agents, browser automation tools, or other automated technologies, is strictly prohibited without prior written authorization from CRISPR Medicine News.
Bulk downloading, systematic querying, data harvesting, indexing, mirroring, or extraction intended to replicate, reconstruct, or commercially exploit substantial portions of the Database is expressly prohibited.
CRISPR Medicine News reserves the right to implement technical countermeasures to detect and prevent unauthorized automated access and to pursue all available legal and equitable remedies in response to violations.
CMN Intelligence Reports - Terms of Use & License Agreement
CRISPR Medicine News (CMN) Global Clinical Trials Reports
Effective Date: 2026-02-17
The CMN Intelligence Reports, including but not limited to the Visual Intelligence Report and Strategic Analytics Report, are analytical publications developed by the CMN Intelligence team at CRISPR Medicine News (CMN).
These reports are derived from data curated within the CRISPR Medicine News Global Clinical Trials Database 2.0, which is manually maintained and continuously updated by the CMN Intelligence team.
CMN Intelligence Reports provide aggregated analysis, interpretation, visualization, and strategic assessment of global clinical trials involving gene-editing technologies, including both:
therapies created using gene editing (e.g., ex vivo gene-edited cell therapies), and
therapies in which gene-editing reagents themselves are administered (e.g., in vivo gene editing).
All figures, analytical frameworks, classifications, commentary, and presentation formats reflect proprietary editorial and analytical work conducted by CMN Intelligence.
Intellectual Property
CMN Intelligence Reports, including their structure, analytical methodology, taxonomy, visualizations, written analysis, figure design, layout, and presentation, are the intellectual property of CRISPR Medicine News, unless otherwise stated.
While underlying clinical trial information originates from publicly available sources — including clinical trial registries, publications, patents, press releases, company disclosures, and regulatory communications — the aggregation, organization, classification, contextualization, and analytical interpretation constitute proprietary intellectual and editorial work developed by CMN Intelligence.
All company names, trademarks, product names, and registered trademarks referenced remain the property of their respective owners.
License Grant
Purchase of a CMN Intelligence Report grants the purchasing organization a non-exclusive, non-transferable license for internal use only, unless otherwise agreed in writing.
The license permits authorized users within the purchasing organization to:
Access and review the report for internal research and decision-making purposes
Circulate the report internally within the licensed organization
Reference insights internally with appropriate attribution to CRISPR Medicine News
Access rights apply solely to the purchasing legal entity and do not extend to affiliates, subsidiaries, partners, clients, or external collaborators unless explicitly licensed.
Permitted Internal Use
Licensed organizations may:
Share the report internally among employees
Use figures or insights in internal strategy discussions
Incorporate findings into internal analyses or evaluations
All internal use must retain attribution to CRISPR Medicine News (CMN Intelligence) where figures or conclusions are referenced.
Restrictions on Use
Without prior written permission from CRISPR Medicine News, users may not:
Redistribute reports outside the licensed organization
Share reports with third parties, including clients, partners, consultants, or investors
Publish or publicly display report content or figures
Include CMN figures or analyses in external publications, marketing materials, press releases, or conference presentations
Use report content in investor or fundraising materials
Resell, sublicense, or commercially exploit report content
Create derivative intelligence products, databases, or analytical services based on CMN content
Systematically extract figures, datasets, classifications, or analytical frameworks
Remove copyright notices or attribution statements
Unauthorized external circulation, including electronic forwarding or public hosting, constitutes prohibited redistribution.
Relationship to the CMN Global Clinical Trials Database 2.0
CMN Intelligence Reports are analytical outputs derived from the CRISPR Medicine News Global Clinical Trials Database 2.0.
Purchase or use of a report does not grant access to the database unless separately licensed.
Use of database content remains subject to the CMN Global Clinical Trials Database 2.0 Terms of Use & License Agreement.
Enterprise & Extended Licensing
Organizations requiring broader usage rights, including external sharing, publication rights, group-wide access, or enterprise distribution, may request extended licensing arrangements.
Please contact CMN Intelligence for enterprise licensing options.
Accuracy & Disclaimer
CMN Intelligence Reports are based on publicly disclosed information available at the time of publication.
While every effort is made to ensure accuracy and completeness, information may be incomplete, updated, corrected, or revised by trial sponsors, regulatory authorities, or other parties without notice.
CRISPR Medicine News does not guarantee the completeness or ongoing accuracy of all information and shall not be responsible for errors, omissions, or subsequent changes in publicly disclosed data.
Reports are provided for informational and analytical purposes only and do not constitute medical, regulatory, investment, or commercial advice.
Enforcement & Remedies
Unauthorized reproduction, redistribution, extraction, or commercial exploitation of CMN Intelligence Reports may constitute violations of applicable copyright, database protection, unfair competition, and contract laws.
CRISPR Medicine News reserves the right to pursue all available legal and equitable remedies, including:
suspension or termination of access
injunctive relief
recovery of damages and legal costs
enforcement under applicable copyright and database protection legislation
Updates to Terms
CRISPR Medicine News reserves the right to update these Terms of Use periodically. Continued use of CMN Intelligence Reports constitutes acceptance of the current version.
Contact
For licensing inquiries, permissions, or enterprise access requests:
Submit your request here.
© 2026 CRISPR Medicine News (CMN). All rights reserved.
Unified Enforcement, Contractual Penalty & Governing Law
This section applies jointly to:
the CRISPR Medicine News (CMN) Global Clinical Trials Database 2.0,
CMN Intelligence Reports, and
any related analytical products, datasets, publications, or services provided by CRISPR Medicine News (collectively, the “CMN Products”).
Material Breach
Any violation of the usage restrictions, licensing limitations, or prohibited conduct described in the applicable Terms of Use or License Agreements governing CMN Products shall constitute a material breach of the applicable agreement.
CRISPR Medicine News may, without prior notice, suspend or terminate access to CMN Products upon detection of such breach.
Contractual Penalty for Unauthorized Use
In the event of unauthorized extraction, scraping, reproduction, redistribution, external sharing, commercial exploitation, creation of derivative databases or intelligence products, or use of CMN Products or their contents for artificial intelligence, machine learning, automated analytics, or similar automated systems without prior written authorization, the violating party agrees to pay CRISPR Medicine News a contractual penalty of EUR 250,000 (two hundred fifty thousand euros) per violation.
The parties acknowledge that this contractual penalty represents a reasonable pre-estimate of damages arising from unauthorized use, including loss of commercial value, competitive harm, loss of exclusivity, investigative and enforcement costs, and reputational damage.
Each unauthorized extraction event, redistribution, automated access activity, AI training use, dataset construction, or prohibited disclosure shall constitute a separate violation.
Payment of the contractual penalty shall not limit CRISPR Medicine News’ right to:
seek injunctive or equitable relief;
terminate licenses or access rights;
recover additional damages where permitted by applicable law; and
recover legal fees, investigation costs, and enforcement expenses.
Governing Law & Jurisdiction
All agreements governing access to or use of CMN Products shall be governed by and construed in accordance with the laws of Denmark, without regard to conflict of law principles.
Any dispute arising out of or in connection with CMN Products or the applicable Terms shall be subject to the exclusive jurisdiction of the competent courts of Denmark.
Nothing in this provision shall limit the right of CRISPR Medicine News to seek injunctive or equitable relief in any jurisdiction where unauthorized use or infringement occurs.
